1. Home
  2. KRNY vs CAPR Comparison

KRNY vs CAPR Comparison

Compare KRNY & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kearny Financial Corp

KRNY

Kearny Financial Corp

N/A

Current Price

$9.53

Market Cap

603.5M

Sector

Finance

ML Signal

N/A

Logo Capricor Therapeutics Inc.

CAPR

Capricor Therapeutics Inc.

HOLD

Current Price

$9.20

Market Cap

584.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KRNY
CAPR
Founded
1884
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Savings Institutions
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
603.5M
584.9M
IPO Year
2014
2011

Fundamental Metrics

Financial Performance
Metric
KRNY
CAPR
Price
$9.53
$9.20
Analyst Decision
Buy
Strong Buy
Analyst Count
2
8
Target Price
$9.25
$44.63
AVG Volume (30 Days)
518.0K
4.6M
Earning Date
04-23-2026
05-12-2026
Dividend Yield
5.45%
N/A
EPS Growth
35.71
N/A
EPS
0.57
N/A
Revenue
$2,580,000.00
N/A
Revenue This Year
$3.89
N/A
Revenue Next Year
$17.52
$3.31
P/E Ratio
$16.75
N/A
Revenue Growth
36.00
N/A
52 Week Low
$6.23
$2.96
52 Week High
$10.24
$40.37

Technical Indicators

Market Signals
Indicator
KRNY
CAPR
Relative Strength Index (RSI) 39.52 51.35
Support Level $9.43 $8.18
Resistance Level $9.74 $11.00
Average True Range (ATR) 0.20 0.60
MACD -0.06 0.20
Stochastic Oscillator 5.06 46.93

Price Performance

Historical Comparison
KRNY
CAPR

About KRNY Kearny Financial Corp

Kearny Financial Corp is a federally-chartered stock savings bank. The bank is engaged in the business of attracting deposits from the general public in New Jersey and New York, and using these deposits, together with other funds, to originate or purchase loans for its portfolios and invest in securities. The bank's loan portfolio is chiefly comprised of loans collateralized by commercial and residential real estate. The bank's primary source of income is net interest income.

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

Share on Social Networks: